CAPTURE: Circulating tumour DNA assessment of PIK3CA to guide treatment response

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1143025

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Many breast cancers shed small amounts of DNA (called circulating tumor DNA or ctDNA) into the patient’s bloodstream. This proposal is for a clinical trial which will examine the use of ctDNA to follow levels of a specific therapeutic target (a mutation in a gene called PIK3CA) in blood, to allow the timely introduction of a targeted therapy (PI3K inhibitor). The trial aims to lead to improved outcomes for women with estrogen receptor positive metastatic breast cancer.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2022

Funding Scheme: Project Grants

Funding Amount: $3,299,064.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Solid Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomarkers | breast cancer | clinical trial | genomics | targeted therapy

Related Links